Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Clinical Trials Post Market Regulation & Studies

Prevnar 13 Post-Market Trials Must Confirm Surrogate Endpoint, Deal With Immunogenicity

  • News

Executive Summary

New post-marketing commitment will look at conjugate pneumonia vaccine when given in patients 50 and older who have already received Merck’s polysaccharide vaccine.

Table

View full table

Advertisement

Related Content

Pink Sheet
Prevnar 13 Recommendation For Medicare Population May Be Short Lived
Pink Sheet
Regulatory News, In Brief
Pink Sheet
Analysis Says Prevnar 13 In Adults Cost-Effective, But Asks Same Questions As ACIP
Pink Sheet
Accelerated Approval Does Not Accelerate ACIP Recommendation For Prevnar 13 In Adults
Pink Sheet
Avastin’s Legacy May Be Quicker Withdrawal Process For New Approval Pathways
Pink Sheet
FDA Indicates Optimism Prevnar 13 Will Show Clinical Benefit In Confirmatory Trial
Pink Sheet
Pfizer Touts Prevnar 13 Superiority As Initial Vaccine In Older Persons Before ACIP

Topics

Related Companies

Advertisement
Tags:
BioPharmaceutical Clinical Trials Post Market Regulation & Studies
UsernamePublicRestriction

Register

PS054086

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By